The Patent Finder

Recombinant DGKK Gene for Fragile X Syndrome Gene Therapy

Universite de Strasbourg

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application PCT/EP2017/074387, filed Sep 26, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 12,799,490Recombinant DGKK Gene for Fragile X Syndrome Gene Therapy
In force
 · High confidence
UsedRemaining
Universite de Strasbourg, Centre National de la Recherche Scientifique and Institut National de la Sante et de la Recherche MedicaleIn forceHigh confidence
US 11,597,936Recombinant DGKK Gene for Fragile X Syndrome Gene Therapy
In force
 · High confidence
Universite de Strasbourg, Centre National de la Recherche Scientifique and Institut National de la Sante et de la Recherche MedicaleIn forceHigh confidence
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited